Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro-Resolving Mediators (MPR-PPI-SPMs)

This is a prospective observational study involving adult patients with severe infection who are admitted to the intensive care unit (ICU). Severe infection and sepsis are major causes of death worldwide. Many patients experience uncontrolled inflammation or immune suppression, but current tests are limited in identifying which patients are at highest risk.

This study focuses on specialized pro-resolving mediators (SPMs), a group of naturally occurring lipid molecules that help the body turn off inflammation and promote healing. Blood samples that are collected during routine clinical care will be used to measure levels of SPMs. No additional blood draws or experimental treatments will be performed.

The purpose of this study is to understand how SPM levels change over time in patients with severe infection and how these changes relate to organ function and outcomes such as survival. By combining SPM measurements with routine laboratory results, immune cell counts, and imaging findings, the study aims to identify different clinical phenotypes and to develop tools that may help doctors recognize high-risk patients earlier in the future.

All participants will receive standard medical care determined by their treating physicians. No experimental drugs or interventions are given as part of this study.

Study Overview

• Status: Not yet recruiting
• Conditions: Sepsis; Critical Illness; Severe Infection; Multiple Organ Dysfunction Syndrome

Detailed Description

Severe infection and sepsis remain leading causes of morbidity and mortality worldwide. Although antimicrobial therapy and organ support have improved, many critically ill patients continue to experience poor outcomes. Increasing evidence indicates that failure to appropriately resolve inflammation plays a key role in organ dysfunction and mortality. Specialized pro-resolving mediators (SPMs) are endogenous lipid mediators that actively terminate inflammation, promote clearance of pathogens and apoptotic cells, and support tissue repair. However, their role in human severe infection has not been systematically investigated in prospective clinical cohorts.

This study is a prospective observational cohort study enrolling adult patients with severe infection admitted to the intensive care unit (ICU). Approximately 300 patients are expected to be included. Peripheral blood samples obtained during routine clinical care on days 1, 3, and 7 after ICU admission will be analyzed. Plasma SPMs, including resolvins, protectins, and maresins, will be quantified using liquid chromatography-tandem mass spectrometry. Routine clinical data, including demographic characteristics, laboratory tests, immune cell subsets, coagulation indicators, severity scores (SOFA and APACHE II), organ support therapies, and 28-day outcomes will be recorded.

The study has four major objectives:

to describe the temporal profiles of SPMs in severe infection

to determine associations between SPM levels and adverse outcomes including 28-day mortality and organ failure

to identify biologically and clinically meaningful phenotypes driven by SPM signatures through multivariate clustering and machine-learning approaches

to explore mechanistic pathways linking SPMs with immune responses, coagulation disturbances, organ dysfunction, and clinical prognosis

No experimental medications or interventional procedures are administered as part of this study. All treatments are determined exclusively by the treating physicians according to routine clinical practice. No genetic testing or DNA extraction will be performed from collected samples.

The expected outcome of this study is the development of an SPM-based precision phenotyping framework that may support individualized risk assessment and potential future therapeutic strategies targeting impaired inflammation resolution.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Shengwei Jin, PhD; Phone Number: +86-15068468153; Email: jinshengwei69@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Adult ICU patients with severe infection or sepsis admitted to a tertiary academic medical center. Both male and female patients aged 18 years or older are eligible. All participants receive standard clinical care, and no experimental treatments are provided within this study.

Description

Inclusion Criteria:

• Age ≥ 18 years
• Admission to the intensive care unit (ICU)
• Diagnosis of severe infection or sepsis, as determined by the treating physician according to current clinical criteria
• Ability to obtain blood samples as part of routine clinical care within 24-48 hours after ICU admission
• Informed consent provided by the patient or legally authorized representative (when applicable)

Exclusion Criteria:

• Known pregnancy
• Known immunosuppressive disease (e.g., hematologic malignancy, advanced HIV infection)
• Use of long-term immunosuppressive therapy or systemic corticosteroids prior to ICU admission
• Pre-existing end-stage disease with expected survival < 28 days (e.g., end-stage cancer receiving palliative care)
• Enrollment in interventional clinical trials that may influence immune or inflammatory responses
• Refusal of informed consent by the patient or legal representative
• Patients in whom blood sampling or follow-up is not feasible (e.g., expected transfer, withdrawal of life-sustaining treatment within 24 hours)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Severe Infection ICU Cohort Adult patients; Adult patients with severe infection admitted to the intensive care unit (ICU). All participants receive standard clinical care as determined by their treating physicians. No experimental interventions are assigned.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
28-day all-cause mortality	All-cause mortality assessed within 28 days after admission to the intensive care unit.	From the date of ICU admission until death from any cause, assessed up to 28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ICU length of stay	Length of stay in the intensive care unit, measured in days from ICU admission to ICU discharge.	From ICU admission to ICU discharge, assessed up to 28 days.
Organ dysfunction	Organ dysfunction assessed using routinely collected clinical data during the first 28 days after ICU admission	Organ dysfunction assessed using routinely collected clinical data from ICU admission through day 28.
Secondary infection during ICU stay	Secondary infection defined as a newly diagnosed infection occurring after ICU admission, confirmed by clinical signs, microbiological evidence, and/or initiation of targeted antimicrobial therapy, based on routinely collected clinical data.	From the date of ICU admission until the occurrence of a secondary infection or ICU discharge, whichever occurred first, assessed up to 28 days

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital of Wenzhou Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): January 15, 2026
• Primary Completion (Estimated): December 16, 2026
• Study Completion (Estimated): January 16, 2028

Study Registration Dates

• First Submitted: January 5, 2026
• First Submitted That Met QC Criteria: January 19, 2026
• First Posted (Actual): January 21, 2026

Study Record Updates

• Last Update Posted (Actual): January 21, 2026
• Last Update Submitted That Met QC Criteria: January 19, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Critical care; Specialized pro-resolving mediators; SPM; Inflammation resolution; Resolvin D1; Immune resolution
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Systemic Inflammatory Response Syndrome; Inflammation; Shock; Pathological Conditions, Signs and Symptoms; Critical Illness; Sepsis; Infections; Multiple Organ Failure
• Other Study ID Numbers: SAHoWMU-CR2025-03-135

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data (IPD) will not be shared because the study involves sensitive clinical information, and data sharing is not covered by the current ethics approval. Data will be used solely for the purposes specified in the approved study protocol.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No